e-learning
resources
Paris 2018
Sunday, 16.09.2018
Primary care management of respiratory conditions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial
H. Watz (Grosshansdorf, Germany), H. Magnussen (Grosshansdorf, Germany), R. Rodriguez-Roisin (Barcelona, Spain), K. Tetzlaff (Ingelheim am Rhein, Germany), M. Haensel (Ingelheim am Rhein, Germany), A. Mueller (Biberach an der Riss, Germany), C. Vogelmeier (Marburg, Germany)
Source:
International Congress 2018 – Primary care management of respiratory conditions
Session:
Primary care management of respiratory conditions
Session type:
Oral Presentation
Number:
289
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Watz (Grosshansdorf, Germany), H. Magnussen (Grosshansdorf, Germany), R. Rodriguez-Roisin (Barcelona, Spain), K. Tetzlaff (Ingelheim am Rhein, Germany), M. Haensel (Ingelheim am Rhein, Germany), A. Mueller (Biberach an der Riss, Germany), C. Vogelmeier (Marburg, Germany). ICS withdrawal and exacerbation risk by GOLD 2017 Report: post hoc analysis of the WISDOM trial. 289
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials
Source: International Congress 2017 – COPD management: new findings from large studies
Year: 2017
Treatment response in COPD: does FEV
1
say it all? A
post hoc
analysis of the CRYSTAL study
Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018
Year: 2019
The impact of grouping patients by the 2017 GOLD COPD strategy on response to therapy: post hoc results from the TONADO tiotropium+olodaterol trials
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017
Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy
Source: International Congress 2017 – COPD management
Year: 2017
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma
Source: International Congress 2018 – Variant forms of asthma
Year: 2018
Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Reduction in asthma exacerbations with indacaterol/glycopyrronium/mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Mortality and exacerbation prediction by GOLD groups ABCD 2011 vs. 2017: analysis of the COPDGene cohort
Source: International Congress 2017 – COPD management: new findings from large studies
Year: 2017
Efficacy of revefenacin based on GOLD 2017 categories: reanalysis of phase 3 data in patients with COPD
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies.
Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases
Year: 2020
Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
An Italian, observational, multicenter trial to describe the therapeutic approach according to COPD GOLD guidelines during three years of observation: The MISTRAL study
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014
Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a
post hoc
analysis from a randomised controlled trial
Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept